X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the financing, Sanofi receives a right of first negotiation to license compounds, including GV101, across various indications, including immunological and metabolic syndrome indications, driving the momentum behind ROCK2 inhibitor treatments.
Lead Product(s): GV101
Therapeutic Area: Immunology Product Name: GV101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Sanofi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing February 01, 2024
Details:
The collaboration will advance clinical development of GV101, which is currently in a Phase 1 trial, along with other selective, small-molecule compounds from a library of ROCK2 inhibitors, that may penetrate the blood-brain barrier.
Lead Product(s): GV101
Therapeutic Area: Neurology Product Name: GV101
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ovid Therapeutics
Deal Size: $10.0 million Upfront Cash: $10.0 million
Deal Type: Collaboration May 01, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
